NeuroSense Secures South Korean Patent for ALS Drug PrimeC, Bolstering Global IP Ahead of Phase 3
NRSN sits 17% above its 52-week low of $0.63 on light trading volume (0.3× avg).
Summary
NeuroSense Therapeutics announced it has been granted a South Korean patent for PrimeC, its lead drug candidate for ALS, strengthening its global intellectual property portfolio as it prepares for Phase 3 development.
Key Events · Product Development and Regulatory · NRSN
-
South Korean Patent Granted for PrimeC
The Korean Intellectual Property Office (KIPO) has issued a patent covering the composition of PrimeC, NeuroSense's lead drug candidate for Amyotrophic Lateral Sclerosis (ALS).
-
Broad IP Protection
The patent claims cover PrimeC's proprietary tablet formulation, manufacturing process, pharmacokinetic characteristics, and pharmaceutical use for the treatment of ALS, providing protection through 2042.
-
Strengthens Global Portfolio
This grant expands NeuroSense's intellectual property protection in a significant pharmaceutical market, following recent patent advancements in Japan, Brazil, Australia, and the United States.
-
Supports Phase 3 Development
The expanded IP portfolio further strengthens the company's position as it prepares to initiate its pivotal Phase 3 PARAGON study for PrimeC in ALS.
Analysis · NRSN · Life Sciences
This patent grant in South Korea is important for NeuroSense as it expands intellectual property protection for PrimeC, their lead ALS drug candidate, in a key pharmaceutical market. Securing patents globally is crucial for a biotechnology company, especially one preparing for pivotal Phase 3 trials. This positive development helps strengthen the company's long-term commercialization strategy and provides a boost to sentiment, particularly given the company's recent 'going concern' warning and Nasdaq compliance issues.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 29.5% of the 1753 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NRSN was trading at $0.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $26M. The 52-week trading range was $0.63 to $2.60. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.